Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02390635 · ClinicalTrials.gov registry record · Phase 1

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

A Phase 1 study of Acute Myeloid Leukemia and Acute Promyelocytic Leukemia With PML-RARA, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
77
Enrollment target
1
Study location

NCT02390635 is a Phase 1 study of Acute Myeloid Leukemia and Acute Promyelocytic Leukemia With PML-RARA that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 77 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02390635, a Phase 1 study of Acute Myeloid Leukemia and Acute Promyelocytic Leukemia With PML-RARA, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
77 participants
Enrollment target
1
Study location

Study Summary

This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.

Conditions Studied

Acute Myeloid Leukemia Acute Promyelocytic Leukemia With PML-RARA

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • DRUG Gadolinium
  • RADIATION Fludeoxyglucose F-18
  • PROCEDURE Diffusion Weighted Imaging

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2020-07-15
Est. Completion 2027-09-15
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02390635

The ClinicalTrials.gov registry entry for NCT02390635 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (34% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT02390635 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02390635 about?

NCT02390635 is a clinical study titled "PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia". This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extr...

What is the current status of trial NCT02390635?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2020-07-15. Estimated completion is 2027-09-15.

What conditions does trial NCT02390635 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA.

What interventions are being tested in trial NCT02390635?

The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Gadolinium (DRUG), Fludeoxyglucose F-18 (RADIATION), Diffusion Weighted Imaging (PROCEDURE).

Who is sponsoring clinical trial NCT02390635?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02390635 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Acute Promyelocytic Leukemia With PML-RARA

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.